Compass Therapeutics, Inc.
Compass Therapeutics, Inc. (CMPX) Revenue
Annual & quarterly revenue history · segment & region breakdown
CMPX · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCompass Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -100.00% |
| 2024-12-31 | $0.00B | +$0.00B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2020-03-31 | $0.00B | +$0.00B | — |
| 2019-03-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare CMPX revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Compass Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Compass Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Compass Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CMPX revenue · 4 questionsCMPX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Compass Therapeutics, Inc. SEC filings · GAAP · Compass Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026